JAZZ
Jazz Pharmaceuticals plc
JAZZ's outlook is improving despite an expensive valuation.
LLY
Eli Lilly and Company
LLY has the edge over JAZZ overall, supported by stronger modeled upside and lower modeled downside.
JAZZ Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Under pressure |
JAZZ's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
JAZZ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.1x | $240 | — |
| Cheap | 15x | $45.24 | -81% |
| Fair | 20x | $62.02 | -74% |
| Current | 78x | $240 | — |
| Expensive | 140x | $430 | +79% |
Historical ranges are pointers, not guarantees.
JAZZ's PE is in its expensive range at 78x. If earnings grow as analysts expect, today's price would be 9.1x next year's earnings, in its cheap range.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over JAZZ in the historical PE scenario, which offers more potential upside but is not a forecast.
JAZZ Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for JAZZ, with profitability improving. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
JAZZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.33 | +758% |
| Q3 2026 | $3.07 | +$9.28 |
| Q2 2026 | $14.63 | +$21.50 |
| Q1 2026 | $0.11 | -99% |
| Q4 2025 | -$5.84 | -168% |
| Q3 2025 | -$6.21 | -188% |
| Q2 2025 | -$6.87 | -218% |
| Q1 2025 | $7.36 | +52% |
| Q4 2024 | $8.65 | +42% |
JAZZ has returned to profit: it earned $3.07 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over JAZZ on earnings, with more consistent year-over-year improvement.
JAZZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +10% |
| Q2 2026 | $1.2B | +16% |
| Q1 2026 | $1.1B | +19% |
| Q4 2025 | $1.2B | +10% |
| Q3 2025 | $1.1B | +6.7% |
| Q2 2025 | $1B | +2.1% |
| Q1 2025 | $897.8M | -0.5% |
| Q4 2024 | $1.1B | +7.5% |
JAZZ's revenue has grown year over year for six quarters in a row: $1.2B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -33% | -38 points |
| Q2 2026 | 21% | +86 points |
| Q1 2026 | 31% | +38 points |
| Q4 2025 | 21% | +3.7 points |
| Q3 2025 | 5.1% | -20 points |
| Q2 2025 | -66% | -85 points |
| Q1 2025 | -6.2% | -14 points |
| Q4 2024 | 18% | +5.4 points |
JAZZ's operating margin was −33% last quarter, down 38 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over JAZZ on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over JAZZ on profitability, with a higher operating margin.
JAZZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $489.9M | +6.6% |
| Q2 2026 | $397.6M | +424% |
| Q1 2026 | $388.5M | -6.6% |
| Q4 2025 | $345.8M | -10% |
| Q3 2025 | $459.4M | +18% |
| Q2 2025 | $75.9M | -77% |
| Q1 2025 | $415.9M | +60% |
| Q4 2024 | $385.3M | +145% |
JAZZ's free cash flow has been positive every quarter for seven years: $1.6B over the past year, up 21% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over JAZZ on cash flow, with more consistent year-over-year improvement.
JAZZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -6.8% | -4.7M shares |
| 1 year | +5% | +3.1M shares |
| 3 years | -9.2% | -6.6M shares |
| 5 years | +5.6% | +3.4M shares |
| Available history | +12% | +7.2M shares |
JAZZ has 65M diluted shares, up 5% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $225M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $150M |
| Q4 2023 | $99.8M |
| Q3 2023 | $74.4M |
| Q4 2022 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over JAZZ on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
JAZZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 5.2x | High |
| Q4 2025 | 14.9x | High |
| Q3 2025 | 21.1x | High |
| Q2 2025 | 11.0x | High |
| Q1 2025 | 2.8x | Moderate |
| Q4 2024 | 2.7x | Moderate |
JAZZ's net debt is about 3.1 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over JAZZ on leverage, with a lower net debt burden relative to earnings.
JAZZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 43.8 | Neutral |
JAZZ's weekly RSI is 58 (neutral) and its Stochastic is 44 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
JAZZ PE vs Healthcare Sector
| Metric | JAZZ | Sector median | Relative |
|---|---|---|---|
| PE | 78x | 26x | 203% above |
| PE % | 81 | 29 | 52 pts above |
JAZZ is trading at 78x earnings, a 203% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over JAZZ on valuation relative to its sector.
JAZZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $225.9 | 6.4% above |
| 20 week MA | $239.1 | 0.5% above |
| 50 week MA | $211.0 | 14% above |
| 100 week MA | $167.5 | 43% above |
| 200 week MA | $146.0 | 65% above |
JAZZ is in an uptrend: it's above all five of its weekly moving averages, and 65% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
JAZZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $150.9 | $157.3 | +4.2% |
| 2021 | $157.3 | $128.2 | -18% |
| 2022 | $128.2 | $157.2 | +23% |
| 2023 | $157.2 | $123.0 | -22% |
| 2024 | $123.0 | $124.6 | +1.3% |
| 2025 | $124.6 | $170.5 | +37% |
| 2026 YTD | $170.5 | $240.4 | +41% |
JAZZ has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.